There is a lot of information in the videos which will take some time to break down in detail.
After a quick viewing, the major takeaways for me were:
1.
More scientific validation from various companies & research institutions.
2. From the last video:
Richard Barker, at a Midkine symposium referencing CAR-T therapy when talking about how targeted treatments need to be accelerated to the clinic.
This inferred to me that Richard classifies Midkine as being in the same class as CAR-T therapy and that he is behind getting it to market fast. *Richard Barker is the founding director of the Centre for the Advancement of Sustainable Medical Innovation. Oxford UK
3.
From the first Video [from 7:54]:
The company has royalty streams and elisa kits generating cash on the Midkine front (Lyramid, Kinera) as well as the Hair Loss revenues in Advangen.
In the context of the 3 subsiduaries (Advangen, Lyramid, Kinera), "We are a revenue generating business and we are reaching profitability in those subsiduaries now." The plurality of the statement indicates profitability across all 3 subsiduaries meaning the entire company!
